10-Q · March 17, 2026
PharmaCyte Biotech, in its Q3 2026 10-Q filing, reported no revenue for the quarter, with a diluted EPS loss narrowing to -$0.17 versus prior quarters. The company has faced increasing general and administrative…
Earnings analysis · 10-Q
PMCB earnings analysis
Filed September 14, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q does not provide income-statement, balance-sheet, cash-flow, segment, or quantitative outlook data, so revenue, margins, EPS, free cash flow, and operating trends cannot be assessed from the available…
Read full summary
The extracted 10-Q does not provide income-statement, balance-sheet, cash-flow, segment, or quantitative outlook data, so revenue, margins, EPS, free cash flow, and operating trends cannot be assessed from the available text. The primary disclosure is that controls were ineffective as of July 31, 2026, with two ongoing material weaknesses involving segregation of duties and management review. The filing states that there were no material changes to the risk factors included in the April 30, 2026 Form 10-K.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Control Effectiveness Disclosed
The company disclosed that its Chief Executive Officer and Chief Financial Officer concluded that disclosure controls were ineffective as of July 31, 2026, due to material weaknesses in internal control over financial reporting.
-
Two Ongoing Control Weaknesses
Management identified two ongoing material weaknesses: insufficient segregation of duties involving the Chief Financial Officer and insufficient management review controls.
What to watch
-
Material Internal-Control Weaknesses
Disclosure controls were not effective as of July 31, 2026, and management identified two ongoing material weaknesses. This raises the risk of errors, delayed reporting, or unreliable financial disclosures.
-
Weaknesses Remain Unremediated
The filing states there were no changes during the three months ended July 31, 2026, that materially affected or were reasonably likely to materially affect internal controls, while the two identified weaknesses remained ongoing.
Management's outlook
No quantitative revenue or EPS guidance is provided in the extracted 10-Q. The filing contains no outlook, liquidity outlook, or capital-spending forecast.
Earlier filings 4
10-Q · December 18, 2025
PharmaCyte Biotech, Inc. reported no revenues for Q2 FY2026, with a diluted EPS of -1.24, reflecting a significant decline in financial performance. Notably, R&D expenses increased to $141,085 from $97,470…
10-Q · September 15, 2025
PharmaCyte Biotech, Inc. reported no revenue for the three months ending July 31, 2025, consistent with the prior year. Research and development expenses decreased slightly to $95,157, while general and administrative…
10-K · August 11, 2025
PharmaCyte Biotech, Inc. reported no revenue for the fiscal year ending April 30, 2025, but showed a significant increase in net income due to gains from investments in preferred stocks and changes in fair market value…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.